Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis.

Jeffrey R CurtisVibeke StrandSteven GolombekLixia ZhangAngus WongMark C ZielinskiViatcheslav R AkmaevAlif SalehSam AsgarianJohanna B Withers
Published in: Expert review of molecular diagnostics (2022)
MSRC clinical validity supports high clinical utility: guided treatment selection resulted in significantly superior outcomes relative to standard care; nearly three times more patients reached CDAI remission.